NCT06533176

Brief Summary

Transcranial magnetic stimulation (TMS) interventions could feasibly strengthen residual corticospinal tract (CST) connections and enhance recovery of paretic upper extremity function after stroke. This project will test whether personalized brain state-dependent TMS can activate the residual corticospinal tract better than standard TMS, and evaluate the relationship between this activation and upper extremity motor impairment.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
37

participants targeted

Target at P25-P50 for not_applicable stroke

Timeline
2mo left

Started Aug 2024

Typical duration for not_applicable stroke

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress88%
Aug 2024Aug 2026

First Submitted

Initial submission to the registry

July 29, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 1, 2024

Completed
Same day until next milestone

Study Start

First participant enrolled

August 1, 2024

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2026

Last Updated

February 3, 2026

Status Verified

January 1, 2026

Enrollment Period

2 years

First QC Date

July 29, 2024

Last Update Submit

January 31, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • MEP amplitudes

    Peak-to-peak MEP amplitudes elicited by single TMS pulses delivered during personalized brain activity patterns corresponding to strong corticospinal transmission and random brain activity patterns will be measured. At the individual participant level, all MEP amplitudes will be normalized to the mean MEP amplitude observed in that participant. Mean normalized MEP amplitudes will be used to calculate the percentage MEP amplitude difference between the two brain activity patterns (i.e., strong and random).

    1 week

  • Upper Extremity Fugl-Meyer Assessment Scores

    Scores obtained for each participant during the Upper Extremity Fugl-Meyer Assessment will be calculated. This will provide a single impairment score that will be correlated with the percentage MEP amplitude difference between brain activity patterns reflecting strong corticospinal transmission and random brain activity patterns.

    1 week

Study Arms (2)

Brain state-dependent TMS during strong states

EXPERIMENTAL
Device: Personalized brain state-dependent single-pulse TMS

Brain state-dependent TMS during random states

ACTIVE COMPARATOR
Device: Personalized brain state-dependent single-pulse TMS

Interventions

Single-pulse TMS will be applied to the lesioned hemisphere during brain activity patterns associated with strong residual corticospinal tract activation and random brain activity patterns.

Brain state-dependent TMS during random statesBrain state-dependent TMS during strong states

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
-Presence of residual upper extremity hemiparesis, defined as any of the following: Fugl Meyer Upper Extremity Score \<66, Wolf Motor Function Test Score \<70, Affected hand performance on the 9-Hole Peg Test \>= 10% worse than unaffected hand, Affected hand pinch, key, or power grip performance \>= 10% worse than unaffected hand, * Occurrence of ischemic or hemorrhagic stroke \>= 6 months before participation * Mini Mental State Exam score \> 24 * Willingness and ability to provide informed consent * No history of neurological disease and/or neurological injury other than stroke * No TMS contraindications, including but not limited to: Cardiac pacemaker, Cochlear implant, Cortical stimulator, Deep brain stimulator, Vagus nerve stimulator, Cervical spine epidural stimulation, Ventriculoperitoneal shunt, Ferromagnetic metallic implants above the level of the seventh cervical vertebra, Seizure in the last 12 months while taking anti-epilepsy medication, History of adverse reactions to TMS or peripheral nerve stimulation, Current, suspected, or planned pregnancy, Any recent changes (within the last month) to medication use \- Presence of residual corticospinal connections innervating an affected upper extremity muscle following stimulation of the lesioned hemisphere (i.e., MEP+), evaluated at rest

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (1)

University of Iowa

Iowa City, Iowa, 52242, United States

RECRUITING

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Central Study Contacts

Sara J Hussain, PhD

CONTACT

Sara J Hussain, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

July 29, 2024

First Posted

August 1, 2024

Study Start

August 1, 2024

Primary Completion (Estimated)

August 1, 2026

Study Completion (Estimated)

August 1, 2026

Last Updated

February 3, 2026

Record last verified: 2026-01

Locations